# Developing therapeutic antibodies for Alzheimer's disease

> **NIH NIH R43** · VERSAPEUTICS INC · 2022 · $498,534

## Abstract

PROJECT SUMMARY/ABSTRACT
 Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to
prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease
result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year.
VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR
project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are
designed to treat Alzheimer’s disease using a unique mechanism of action, by examining pharmacokinetics,
efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important
milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.

## Key facts

- **NIH application ID:** 10484675
- **Project number:** 1R43AG078094-01
- **Recipient organization:** VERSAPEUTICS INC
- **Principal Investigator:** Miao Sun
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $498,534
- **Award type:** 1
- **Project period:** 2022-08-01 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10484675

## Citation

> US National Institutes of Health, RePORTER application 10484675, Developing therapeutic antibodies for Alzheimer's disease (1R43AG078094-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10484675. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*